Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1625297 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $40.22Day +0.30%Mkt cap $4.9BP/E (FY) 24.5×1Y +131.1%Off 52W high −6.0%Vol (1Y) 39.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 781 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Fair value (model)$21.42 |
| Implied upside−46.6% |
| Valuation confidenceLOW |
| Price impliesHEROIC · 28.4% growth |
| Short interest9.2% of sh out |
| Days to cover7.6d |
| 13F net flow (QoQ)−1.69% |
| Top-10 13F concentration51.5% |
| Next report (est.)2026-10-29 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)24.5× |
| Sales (TTM)$1.29B |
| YTD+12.1% |
| 1Y+131.1% |
| 3Y+80.9% |
| Since incept. (ann.)+19.9% |
Total return through 2026-07-30 · series begins 2023-06-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)39.8% |
| Ann. volatility (3Y)55.6% |
| Sharpe (1Y)2.36 |
| Sharpe (3Y)0.64 |
| Max drawdown (1Y)−21.4% |
| Max drawdown (3Y)−68.8% |
| Beta (3Y vs SPY)1.07 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 18.5M | $565M | 14.83% | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.9M | $241M | 6.31% | new |
| OAKTREE CAPITAL MANAGEMENT LP | 7.0M | $213M | 5.58% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.6M | $170M | 4.47% | new |
| STATE STREET CORP | 4.9M | $149M | 3.92% | new |
| Two Seas Capital LP | 4.7M | $145M | 3.80% | new |
| MILLENNIUM MANAGEMENT LLC | 4.6M | $140M | 3.67% | new |
| FULLER & THALER ASSET MANAGEMENT, INC. | 4.5M | $138M | 3.62% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 102.0% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 12,824,697 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-30 | $0.69 | +81.6% | $317.0M | +19.2% |
| 2025-12-31 | 2026-02-26 | — | — | $357.0M | +19.8% |
| 2025-09-30 | 2025-10-30 | $0.33 | +106.3% | $314.0M | +2.3% |
| 2025-06-30 | 2025-07-31 | $0.14 | — | $302.0M | +1.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-29 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Earnings (TTM)$252.0M |
| Net margin16.9% |
| Total debt / EBITDA1.17× |
| Sales growth 3Y11.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
